Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript March 5, 2024
Marinus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.74 EPS, expectations were $-0.64. Marinus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Ladies and gentlemen, greetings and welcome to Marinus Pharmaceuticals’ Fourth Quarter and Full Year 2023 Financial Results and...
